UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 7, 2014
CYTORI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-34375
|
33-0827593
|
|
(State or other jurisdiction of incorporation)
|
(Commission File
Number)
|
(I.R.S. Employer Identification No.)
|
3020 Callan Road, San Diego, California 92121
(Address of principal executive offices) (Zip Code)
(858) 458-0900
(Registrant's telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
|
□
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
□
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
□
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) Effective June 7, 2014, pursuant to the recommendation of the Governance and Nominating Committee, the Board of Directors (the “Board”) of Cytori Therapeutics, Inc. (the “Company”) appointed Ruud J. P. Jona to serve as a director of the Company for a term expiring at the Company’s 2014 annual meeting of stockholders, or until his successor is duly elected and qualified or his earlier death, resignation or removal.
Mr. Jona was elected pursuant to that certain Stock Purchase Agreement, dated October 29, 2013, by an between the Company and Lorem Vascular Pty. Ltd, a company organized under the laws of Australia (“Lorem Vascular”), pursuant to which the Company granted to Lorem Vascular the right to appoint one designated individual to serve on the Board. There are no transactions in which Mr. Jona has an interest requiring disclosure under Item 404(a) of Regulation S-K.
In connection with his services as a director, Mr. Jona will be entitled to the customary compensatory arrangements for our outside directors. In addition, on June 7, 2014, Mr. Jona was granted an option to purchase twenty-one thousand (21,000) shares of our common stock pursuant to the terms of our 2004 Equity Incentive Plan, at an exercise price per share of $2.32, which was the fair market value of our common stock on the date of grant. The option vests fifty percent (50%) on June 7, 2015 with the remaining options vesting in equal monthly installments over the subsequent year thereafter, subject to Mr. Jona’s continued service to the Company. On June 7, 2014, Mr. Jona was also granted 21,000 shares of restricted stock pursuant to the terms of our 2004 Equity Incentive Plan. The restricted stock vests fifty percent (50%) on June 7, 2015 and fifty percent (50%) on June 7, 2016, subject to Mr. Jona’s continued service to the Company.
The Company issued a press release announcing the appointment of Mr. Jona to the Board, a copy of which is filed hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
________________________________________
99.1 Press Release June 12, 2014
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CYTORI THERAPEUTICS, INC.
|
||
|
Date: June 12, 2014
|
By:
|
/s/ Mark E. Saad
|
|
Mark E. Saad
|
||
|
Chief Financial Officer
|
||
Exhibit Index
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release dated June 12, 2014
|
|
CYTORI THERAPEUTICS CONTACT
|
|
Megan McCormick
|
|
+1.858.875.5279
|
|
mmccormick@cytori.com
|
Cytori Appoints Ruud J.P. Jona and Nominates Gail K. Naughton to Board of Directors
SAN DIEGO, June 12, 2014 – Cytori Therapeutics (NASDAQ: CYTX) today announced that the Company’s Board of Directors has appointed Ruud J.P. Jona to serve as a director of the Company. Mr. Jona was appointed pursuant to the Stock Purchase Agreement, dated October 29, 2013, by and between the Company and Lorem Vascular, pursuant to which the Company granted to Lorem Vascular the right to appoint one designated individual to serve on the Board.
“Mr. Jona has more than 25 years of international management and sales and marketing experience,” said Dr. Marc Hedrick, President and CEO of Cytori. “His experience in efficiently capitalizing, scaling and managing complex global businesses will be very valuable to the board and the management of Cytori.”
Cytori entered into a strategic relationship with Lorem Vascular, a company founded by Australian businessman K.T. Lim with the purpose of commercializing Cytori Cell Therapy in China and parts of Asia, in October 2013. Lorem Vascular will be initially focused on the cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia.
In addition to the appointment of Mr. Jona, Cytori has nominated Gail K. Naughton, PhD to serve as an independent director on the Board of Directors. If accepted, the appointment will become effective July 1, 2014.
About Ruud J.P. Jona
Mr. Jona served on the Board of various Riverside-owned companies and served as Chief Executive Officer of Philips Central Europe, as Chief Executive Officer of Philips Malaysia and held other management and sales and marketing roles at the company. Mr. Jona has served on the Board of a number of companies including Vokes Air Holding AB, Teufel GMBH and Think Appliances Pty Ltd. He holds a B.A. in Business Administration from the European University of Antwerp in Belgium and a M.B.A. from the University of Dallas.
About Gail K. Naughton, PhD.
Dr. Naughton is a pioneer in the field of regenerative medicine. She was the co-founder and co-inventor of the technology at Advanced Tissue Sciences where she held key management positions for more than 15 years, including President, Chief Operating Officer and Director. She also served as the Dean of the College of Business Administration at San Diego State University for nine years. Currently, Dr. Naughton serves as the Chief Executive Officer and the Chairman of the Board of Histogen, a regenerative medicine company she founded in 2007. Dr. Naughton also currently serves on the Board of Directors for CR Bard, Inc. Dr. Naughton holds a B.S. in Biology from St. Francis College as well as a Master’s in Histology and a PhD from New York University Medical Center. She also holds an EMBA from the Anderson School at the University of California, Los Angeles.
About Cytori Therapeutics
Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs™) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs™ improve blood flow, modulate the inflammatory response and rescue tissue at risk of dying. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® System product family. www.cytori.com
###